Basic Information
Teacher Name:JUNG, Yong Sam
Job Title: Professor
Phone：025-84399102
Email：ysjung@njau.edu.cn
Address：Teaching Building B419-1
Research Areas and Descriptors：
Virus-host interaction
Diagnosis and prevention of infectious diseases
Profile
Introduction:
Dr. Jung obtained a PhD degree in 2005 from PaiChai University, Korea, major in Genetic Engineering. After that, Dr. Jung had been worked as a Researcher at Institute of Biotechnology at Chungnam National University, Korea from 2005-2007 and a Post-doctoral fellow at University of California at Davis, USA from 2007 to 2013. Since 2013, Dr. Jung has been employed as a professor at College of Veterinary Medicine, Nanjing Agricultural University, China. Dr. Jung’s current research is focused on: 1) characterize the role of protein homeostasis in virus pathogenesis, including coronavirus and influzenza virus; 2) Development of diagnosis, antiviral agents and vaccines for coronavirus, influenza, emerging and reemerging viruses. Dr. Jung has published more than 28 research papers in the international journals and more than 7 domestic and international patents.
Research Funding:
1. 2017-2020Fundamental Research Funds for the CentralUniversities(KYHW201702)
2. 2014-2016 Fundamental Research Funds for the CentralUniversities(Y0201300526)
3. 2013 –NAU startup funding
1st Author Research Articles
1. Lian X, Ming X, Xu J, Cheng W, Zhang X, Chen H, Ding C, Jung YS*, Qian Y*. First molecular detection and characterization of Marek's disease virus in red-crowned cranes (Grus japonensis): a case report.BMC Vet Res, 2018,14(1):122.
2. Sun H, Yao W, Wang K, Qian Y, Chen H*, Jung YS*. Inhibition of neddylation pathway represses influenza virus replication and pro-inflammatory responses. 2018 Virology, 514:230-239.
3. Liu XD, Qian Y, Jung YS*and Chen PY*. Isolation and immunomodulatory activity of bursal peptide, a novel bursal peptide from the chicken bursa of Fabricius. J Vet Sci 201516(4):501-7. (*Co-corresponding author)
4. Jung YS, Qian Y, Yan W, and Chen X. Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. 2013 J. Investi. Dermatol., 133(5):1178-87. (*Top 1 in the dermatology field; Featured on MDlinx.com).
5. Qian Y*, Jung YS*, and Chen X. DEC1 controls the response of p53-dependent cell survival versus cell death to a stress signal through macrophage inhibitory cytokine-1. Proc Natl AcadSci USA 2012; 109, 11300-11305. (*These authors contributed equally to the work).
6. Jung YS, Qian Y, and Chen X. DNA polymerase eta is targeted by Mdm2 for polyubiquitination and proteasomal degradation in response to ultraviolet irradiation. DNA Repair (Amst) 2012; 11(2), 177-184.
7. Jung YS, Qian Y, and Chen X. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J BiolChem 2011; 286, 35388-35395.
8. Jung YS, Hakem A, Hakem R, and Chen X. Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis. Mol Cell Biol 2011; 31, 3997-4006.
9. Jung YS, Liu G, and Chen X. Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation. Mol Cell Biol 2010; 30, 1041-1048.
10. Jung YS, Kim HY, Lee MG, Pouyssegur J, and Kim E. Physical interaction and functional coupling between Daxx and sodium hydrogen exchanger isoform 1 in ischemic stress-induced cell death. J BiolChem 2008; 283, 1018-1025.
11. Jung YS, Kim HY, Lee YJ, and Kim E. Subcellular localization of Daxx determines its opposing functions in ischemic cell death. FEBS Lett 2007; 581, 843-852.
12. Jung YS, Lee DH, Lim H, Yi KY, Yoo SE, and Kim E. KR-31378 protects cardiac H9c2 cells from chemical hypoxia-induced cell death via inhibition of JNK/p38 MAPK activation. Jpn J physiol2004; 54, 575-583.
13. Jung YS, Jung YS, Kim MY, and Kim E. Identification of caspase-independent PKCε-JNK/p38 MAPK signaling module in response to metabolic inhibition in H9c2 cells. Jpn J physiol 2004; 54, 23-29.
14. Jung YS, Kim, KS, Kim, KD, Lim, JS, Kim, JW, and Kim, E. Apoptosis-linked gene 2 binds to the death domain of Fas and dissociates from Fas during Fas-mediated apoptosis in Jurkat cells. BiochemBiophys Res Commun 2001; 288, 420-426.
Collaborated Research Articles:
1. Ming X,Bao CY, Hong T, Yang Y, Chen X, Jung YS, Qian Y. Clusterin, a novel DEC1 target, modulates DNA damage-mediated cell death. Mol Cancer Res, 2018 (Accepted).
2. Zhang Y, Qian Y, Zhang J, Yan W, Jung YS, Chen M, Lloyd K, Duan Y, Wang J, Liu G, and Chen X. Ferredoxin Reductase Is Critical for p53-Dependent Tumor Suppressionvia Iron Regulatory Protein 2.2017 Genes&Dev. Published online July 26. doi:10.1101/gad.299388.117
3. Liu K, Zhou B, Wang F, Huan B, Shao D, Wei J, Qiu Y, Li B, Qian Y, Jung YS, Miao D, Tong G, and Ma Z. A conjugate protein containing HIV TAT, ISG20, and a PRRSV polymerase bindinginhibits PRRSV replication and may be a novel therapeutic platform. 2017 Res Vet Sci. 113:13-20.
4. Liu K, Qian Y, Jung YS, Zhou B, Cao R, Shen T, Shao D, Wei J, Ma Z, Chen P, Zhu H, and Qiu Y. mosGCTL-7, a C-type lectin protein, mediates Japanese encephalitis virus infection in mosquitoes.J Virol2017 Mar 1 (Epub ahead of print)
5. Yan W, Scoumanne A, Jung YS, Xu E, Zhang J, Zhang Y, Ren C, Sun P and Chen X. Mice deficient in poly(C)-binding protein 4 are susceptible to spontaneous tumors through increased expression of ZFP871 that targets p53 for degradation. Genes&Dev. 201630(5):522-34.
6. Cho SJ, Teng IF, Zhang M, Yin T, Jung YS, Zhang J and Chen X. Hypoxia-inducible factor 1 alpha is regulated by RBM38, a RNA-binding protein and a p53 family target, via mRNA translation. Oncotarget 20156(1):305-16.
7. Ren C,Cho SJ, Jung YSand Chen X. DNA polymerase η is regulated by poly(rC)-binding protein 1 via mRNA stability. Biochem J2014464(3):377-86.
8. Yan W, Jung YS, Zhang Y and Chen X. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. PLoS One20149(8):e103497.
9. Qian Y, Zhang J, Jung YS, Chen X. DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ΔNp73 expression. PLoS One. 2014 Jan 3;9(1):e84015.
10. Cho SJ, Rossi A, Jung YS, Yan W, Liu G, Zhang J, Zhang M, Chen X. Ninjurin1, a target of p53, regulates p53 expression and p53-dependent cell survival, senescence, and radiation-induced mortality. Proc Natl AcadSci USA. 2013;110(23):9362-7.
11. Cho SJ, Jung YS, Chen X. Poly (C)-binding protein 1 regulates p63 expression through mRNA stability. PLoS One. 2013 Aug 7;8(8):e71724.
12. Yan W, Chen X, Zhang Y, Zhang J, Jung YS, Chen X. Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein. J Biol Chem. 2013;288(5):2907-13.
13. Yan W, Zhang J, Zhang Y, Jung YS, Chen X. P73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol. 2012; 32, 2336-2348.
14. Cho SJ, Jung YS, Zhang J, Chen X. The RNA-binding Protein RNPC1 Stabilizes the mRNA Encoding the RNA-binding Protein HuR and Cooperates with HuR to Suppress Cell Proliferation. J BiolChem 2012;287(18),14535-14544.
15. Zhang Y, Yan W, Jung YS, Chen X. Mammary epithelial cell polarity is differentially regulated by p73 isoforms via epithelial-to-mesenchymal transition. J BiolChem 2012;287(21), 17746-17753.
16. SeoKw, Holt R, Jung YS, Rodriguez CO Jr, Chen X, Rebhun RB. Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines. PLoS One. 2012;7(8):e42960.
17. Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, and Hakem R. Role of Pirh2 in Mediating the Regulation of p53 and c-Myc. PLoS Genet2011; 11, e1002360.
18. Qian Y, Jung YS, and Chen X. DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation. J BiolChem2011; 286,12033-12041.
19. Hwang IS, Jung YS, and Kim E. Interaction of ALG-2 with ASK1 influences ASK1 localization and subsequent JNK activation.FEBS Lett 2002; 529, 183-187.
20. Kim ES, Yoo SE, Yi KY, Lee S, Noh JS, Jung YS, Kim E, and Jeong N. Design, Syntheses and Biological Evaluations of Nonpeptidic Caspase 3 Inhibitors. Bull Korean ChemSoc 2002; 23, 1003-1010.
21. Cho SJ, Lee NS, Jung YS, Lee H, Lee KJ, Kim E, and Chae SK. Identification of structural domains affecting transactivation potential of Nm23. BiochemBiophys Res Commun 2001; 289, 738-743.
Invited Review Articles:
1. Ming X, Jung YS,Babiuk LA, Qian Y. The Host Signaling Pathways Hijacked by On-cogenic Viruses. SM Vaccine Vaccin. 2017; 3(1): 1020
2. Jung YS, Qian Y, and Chen X. Pirh2 RING-finger E3 ubiquitin ligase: Its role in tumorigenesis and cancer therapy. FEBS Lett 2012; 586, 1397-1402.
3. Jung YS, Qian Y, and Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010; 22, 1003-1012.
4. Qian Y, Jung YS, Chen X. DEC1 and MIC-1: new players of p53-dependent cell fate decision. Cell Cycle. 2012;11(19):3525-6.
Patents
- Issued patents
1. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2012, Japan, 2009-534498.
2. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2012, China, 200780040117.0.
3. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2011, Canada, 266975.
4. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2011, USA, 7939550.
5. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2011, Australia, 2007309854.
6. Seo JH, Yoo SE, YiKY, Kim N, Kim E, Jung YS, Lee YS, Suh Kim HY.Benzofuran and Benzothiophene derivatives substituted by amide, process for the preparation thereof, and pharmaceutical compositions containing the same. 2010, Korea patent no. 10-2007-0103244.
7. Seo JH, Yoo SE, Yi KY, Kim N, Kim E, Jung YS, Lee YS, Suh Kim HY. Composition for preventing or treating an ischemic disease containing aminothiophene derivatives. 2008, Korea patent no. 10-0860539.
8. Seo JH, Yoo SE, Yi KY, Kim N, Kim E, Jung YS, Lee, YS, Suh Kim HY. N-phenylamide derivatives and preparation method thereof. 2008, Korea patent no. 10-0832751.
9. SeoJH, Yoo SE, Kim N, Kim E, Jung YS, Lee YS, Suh Kim HY. Composition for preventing or treating an ischemic disease containing N-phenylamide derivatives. 2008, Korea patent no. 10-0832750.
10. Jung YS, Kim E, Kim N, Lee YS, Seo JH, Suh Kim HY, Yi KY and Yoo SE.Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2008, Korea patent no 10-0832747.
11. Kim E, Lee YS, Jung YS, Yoo SE, Seo JH, Chae SK, and Lee KJ. Composition for treating an ischemic disease comprising a human FAF1 protein inhibitor as an active ingredient. 2008, Korea patent no. 10-0818752.
12. Jung YS, Lee DH, Kim E, and Lim H. Human Daxx protein and a fragment thereof as binding agents of human NHE1 ion channel protein. 2006, Korea patent no. 10-0597615-0000.
- Submitted patents
1. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. 2009, India, 3321/DELNP/ 2009.
2. Jung YS, Kim E, Kim NJ, Lee YS, Suh JH, Suh Kim HY, Yi KY, and Yoo SE. Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same. EPO, 2009, 07833620.3.
3. Suh JH, Yoo SE, Yi KY, Kim NJ, Kim E, Jung YS, Lee YS, and Suh Kim HY. Benzofuran and benzothiophene derivatives substituted by amide, process for the preparation thereof, and pharmaceutical compositions containing the same. PCT, 2008, PCT/ KR2008/ 005933.
4. Suh JH, Yoo SE, Yi KY, Kim NJ, Kim E, Jung YS, Lee YS, and Suh Kim HY. Use of aminothiophene derivative for preventing or treating ischemic diseases. PCT, 2008, PCT/ KR2008/ 002594.
5. Suh JH, Yoo SE, Yi KY, Kim NJ, Kim E, Jung YS, Lee YS, and Suh Kim HY. N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic disease comprising same. PCT, 2007, PCT/ KR2007/ 006351.
